Palmar Fibromatosis – 180-Day Clinical Study Abstract
VIEW REPORT
A Study of the Safety of Progeneron Hand Cream in Subjects with Palmar Fibromatosis
VIEW REPORT
Clinical Safety Evaluation Repeated Insult Patch Test – Progeneron DupurtyRx
VIEW REPORT
Advances in Human Islet Processing: Manufacturing Steps to Achieve Predictable Islet Outcomes from Research Pancreases
This presentation of a six-year study processing human islets for research and transplantation includes a review of multi-center transplant studies identifying key variables critical for successful islet processing and defines standardized processing procedures required to provide highly purified, functional Human Islets. Methods:Human islet processing methods are defined in detail with pancreas retrieval, shipping, trimming for […]
Encapsulated Human Islet Allografts: Providing Safety with Efficacy
The general consensus among transplant centers is that a cold ischemia time (CIT) beyond 8 hours results in reduced yields and quality of human islets.
Islet Isolation From Human Pancreas With Extended Cold Ischemia Time
The general consensus among transplant centers is that a cold ischemia time (CIT) beyond 8 hours results in reduced yields and quality of human islets.
90 IRB (Institutional Review Board) Safety Study #Pro0045656 – 29 Subjects with Palmar Fibromatosis = Safe for Use
The Role of Progeneron Hand Cream (PHC) in Persons with Early and Advanced Dupuytren’s Disease and Contractures
David W. Scharp, MD, FACS About the Author Dr. David W. Scharp, MD, is a scientist, surgeon, researcher, and a former tenured Professor of Surgery at Washington University St. Louis (Barnes Hospital). He has developed Dupuytren’s Disease and Contractures. Dr. Scharp was a co-founder and Chief Scientific Officer of Novocell (ViaCyte). Dr. Scharp founded the […]